Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?
[BACKGROUND] For de-novo oligometastatic prostate cancer (omHSPC) treated with standard of care androgen suppression and prostate radiotherapy, the patterns of progression vis-a-vis index metastatic s
- 추적기간 39 months
APA
Verma P, Maitre P, et al. (2025). Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?. Prostate cancer and prostatic diseases. https://doi.org/10.1038/s41391-025-01056-6
MLA
Verma P, et al.. "Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?." Prostate cancer and prostatic diseases, 2025.
PMID
41372716
Abstract
[BACKGROUND] For de-novo oligometastatic prostate cancer (omHSPC) treated with standard of care androgen suppression and prostate radiotherapy, the patterns of progression vis-a-vis index metastatic sites are not well understood.
[METHODS] This single-centre study included patients with de-novo omHSPC (CHAARTED criteria) staged with a PSMA-PET/CT scan at diagnosis, treated with systemic therapy and prostate radiotherapy, and re-staged with PSMA-PET/CT at biochemical progression. Disease status at index oligometastases was noted at progression.
[RESULTS] From 2015 to 2024, 79 patients with omHSPC were found eligible (M1a = 22, M1b = 57). Over a median follow-up of 39 months (IQR 28-69), 15 patients (19%) had disease progression. Restaging PSMA-PET/CT revealed progression of the index oligometastases for 11/15 patients (73%), with additional metastases in 7 of these.
[CONCLUSION] The high proportion of progression at the index oligometastases supports the potential benefit of metastasis-directed therapy for local ablation.
[METHODS] This single-centre study included patients with de-novo omHSPC (CHAARTED criteria) staged with a PSMA-PET/CT scan at diagnosis, treated with systemic therapy and prostate radiotherapy, and re-staged with PSMA-PET/CT at biochemical progression. Disease status at index oligometastases was noted at progression.
[RESULTS] From 2015 to 2024, 79 patients with omHSPC were found eligible (M1a = 22, M1b = 57). Over a median follow-up of 39 months (IQR 28-69), 15 patients (19%) had disease progression. Restaging PSMA-PET/CT revealed progression of the index oligometastases for 11/15 patients (73%), with additional metastases in 7 of these.
[CONCLUSION] The high proportion of progression at the index oligometastases supports the potential benefit of metastasis-directed therapy for local ablation.
같은 제1저자의 인용 많은 논문 (4)
- Evaluation of Patterns of Recurrences in Patients With Breast Carcinoma: Are We Treating the Right Volumes, or Does the Tumor Biology Play the Role?
- Comparative Analysis of Stromal Tumor Infiltrating Lymphocytes in Various Grades and Molecular Subtypes of Breast Carcinoma.
- Comparative evaluation of surgical outcomes in acute acquired comitant esotropia managed with and without pre-operative prism adaptation test.
- Rare Presentations of Differentiated Thyroid Cancer Exposing Dr Jekyll and Mr Hyde Nature of an Otherwise Indolent Disease: Case Series.